Immuno-Oncology-Global Market Status and Trend Report 2016-2026
Report Summary
Immuno-Oncology-Global Market Status and Trend Report 2016-2026 offers a comprehensive analysis on Immuno-Oncology industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Immuno-Oncology 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Immuno-Oncology worldwide, with company and product introduction, position in the Immuno-Oncology market
Market status and development trend of Immuno-Oncology by types and applications
Cost and profit status of Immuno-Oncology, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Immuno-Oncology market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Immuno-Oncology industry.
The report segments the global Immuno-Oncology market as:
Global Immuno-Oncology Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Immuno-Oncology Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Global Immuno-Oncology Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
Hospitals
Drugstores
Others
Global Immuno-Oncology Market: Manufacturers Segment Analysis (Company and Product introduction, Immuno-Oncology Sales Volume, Revenue, Price and Gross Margin):
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Immuno-Oncology-Global Market Status and Trend Report 2016-2026 offers a comprehensive analysis on Immuno-Oncology industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Immuno-Oncology 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Immuno-Oncology worldwide, with company and product introduction, position in the Immuno-Oncology market
Market status and development trend of Immuno-Oncology by types and applications
Cost and profit status of Immuno-Oncology, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Immuno-Oncology market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Immuno-Oncology industry.
The report segments the global Immuno-Oncology market as:
Global Immuno-Oncology Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Immuno-Oncology Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Global Immuno-Oncology Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
Hospitals
Drugstores
Others
Global Immuno-Oncology Market: Manufacturers Segment Analysis (Company and Product introduction, Immuno-Oncology Sales Volume, Revenue, Price and Gross Margin):
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF IMMUNO-ONCOLOGY
1.1 Definition of Immuno-Oncology in This Report
1.2 Commercial Types of Immuno-Oncology
1.2.1 Immune Checkpoint Inhibitors
1.2.2 Cytokine-Based Immunotherapy
1.2.3 Cancer Vaccines
1.2.4 CAR-T Cell Therapy
1.2.5 Others
1.3 Downstream Application of Immuno-Oncology
1.3.1 Hospitals
1.3.2 Drugstores
1.3.3 Others
1.4 Development History of Immuno-Oncology
1.5 Market Status and Trend of Immuno-Oncology 2016-2026
1.5.1 Global Immuno-Oncology Market Status and Trend 2016-2026
1.5.2 Regional Immuno-Oncology Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Immuno-Oncology 2016-2021
2.2 Production Market of Immuno-Oncology by Regions
2.2.1 Production Volume of Immuno-Oncology by Regions
2.2.2 Production Value of Immuno-Oncology by Regions
2.3 Demand Market of Immuno-Oncology by Regions
2.4 Production and Demand Status of Immuno-Oncology by Regions
2.4.1 Production and Demand Status of Immuno-Oncology by Regions 2016-2021
2.4.2 Import and Export Status of Immuno-Oncology by Regions 2016-2021
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Immuno-Oncology by Types
3.2 Production Value of Immuno-Oncology by Types
3.3 Market Forecast of Immuno-Oncology by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Immuno-Oncology by Downstream Industry
4.2 Market Forecast of Immuno-Oncology by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMMUNO-ONCOLOGY
5.1 Global Economy Situation and Trend Overview
5.2 Immuno-Oncology Downstream Industry Situation and Trend Overview
CHAPTER 6 IMMUNO-ONCOLOGY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Immuno-Oncology by Major Manufacturers
6.2 Production Value of Immuno-Oncology by Major Manufacturers
6.3 Basic Information of Immuno-Oncology by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Immuno-Oncology Major Manufacturer
6.3.2 Employees and Revenue Level of Immuno-Oncology Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 IMMUNO-ONCOLOGY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Bristol-Myers Squibb
7.1.1 Company profile
7.1.2 Representative Immuno-Oncology Product
7.1.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.2 Merck & Co., Inc.
7.2.1 Company profile
7.2.2 Representative Immuno-Oncology Product
7.2.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.3 Roche AG
7.3.1 Company profile
7.3.2 Representative Immuno-Oncology Product
7.3.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Roche AG
7.4 AstraZeneca, Plc
7.4.1 Company profile
7.4.2 Representative Immuno-Oncology Product
7.4.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of AstraZeneca, Plc
7.5 Sanofi S.A.
7.5.1 Company profile
7.5.2 Representative Immuno-Oncology Product
7.5.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Sanofi S.A.
7.6 Dendreon Pharmaceuticals
7.6.1 Company profile
7.6.2 Representative Immuno-Oncology Product
7.6.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Dendreon Pharmaceuticals
7.7 Novartis
7.7.1 Company profile
7.7.2 Representative Immuno-Oncology Product
7.7.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Novartis
7.8 Gilead Sciences Inc.
7.8.1 Company profile
7.8.2 Representative Immuno-Oncology Product
7.8.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Gilead Sciences Inc.
7.9 Merck KGaA
7.9.1 Company profile
7.9.2 Representative Immuno-Oncology Product
7.9.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Merck KGaA
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMMUNO-ONCOLOGY
8.1 Industry Chain of Immuno-Oncology
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMMUNO-ONCOLOGY
9.1 Cost Structure Analysis of Immuno-Oncology
9.2 Raw Materials Cost Analysis of Immuno-Oncology
9.3 Labor Cost Analysis of Immuno-Oncology
9.4 Manufacturing Expenses Analysis of Immuno-Oncology
CHAPTER 10 MARKETING STATUS ANALYSIS OF IMMUNO-ONCOLOGY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Immuno-Oncology in This Report
1.2 Commercial Types of Immuno-Oncology
1.2.1 Immune Checkpoint Inhibitors
1.2.2 Cytokine-Based Immunotherapy
1.2.3 Cancer Vaccines
1.2.4 CAR-T Cell Therapy
1.2.5 Others
1.3 Downstream Application of Immuno-Oncology
1.3.1 Hospitals
1.3.2 Drugstores
1.3.3 Others
1.4 Development History of Immuno-Oncology
1.5 Market Status and Trend of Immuno-Oncology 2016-2026
1.5.1 Global Immuno-Oncology Market Status and Trend 2016-2026
1.5.2 Regional Immuno-Oncology Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Immuno-Oncology 2016-2021
2.2 Production Market of Immuno-Oncology by Regions
2.2.1 Production Volume of Immuno-Oncology by Regions
2.2.2 Production Value of Immuno-Oncology by Regions
2.3 Demand Market of Immuno-Oncology by Regions
2.4 Production and Demand Status of Immuno-Oncology by Regions
2.4.1 Production and Demand Status of Immuno-Oncology by Regions 2016-2021
2.4.2 Import and Export Status of Immuno-Oncology by Regions 2016-2021
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Immuno-Oncology by Types
3.2 Production Value of Immuno-Oncology by Types
3.3 Market Forecast of Immuno-Oncology by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Immuno-Oncology by Downstream Industry
4.2 Market Forecast of Immuno-Oncology by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMMUNO-ONCOLOGY
5.1 Global Economy Situation and Trend Overview
5.2 Immuno-Oncology Downstream Industry Situation and Trend Overview
CHAPTER 6 IMMUNO-ONCOLOGY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Immuno-Oncology by Major Manufacturers
6.2 Production Value of Immuno-Oncology by Major Manufacturers
6.3 Basic Information of Immuno-Oncology by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Immuno-Oncology Major Manufacturer
6.3.2 Employees and Revenue Level of Immuno-Oncology Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 IMMUNO-ONCOLOGY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Bristol-Myers Squibb
7.1.1 Company profile
7.1.2 Representative Immuno-Oncology Product
7.1.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.2 Merck & Co., Inc.
7.2.1 Company profile
7.2.2 Representative Immuno-Oncology Product
7.2.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.3 Roche AG
7.3.1 Company profile
7.3.2 Representative Immuno-Oncology Product
7.3.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Roche AG
7.4 AstraZeneca, Plc
7.4.1 Company profile
7.4.2 Representative Immuno-Oncology Product
7.4.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of AstraZeneca, Plc
7.5 Sanofi S.A.
7.5.1 Company profile
7.5.2 Representative Immuno-Oncology Product
7.5.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Sanofi S.A.
7.6 Dendreon Pharmaceuticals
7.6.1 Company profile
7.6.2 Representative Immuno-Oncology Product
7.6.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Dendreon Pharmaceuticals
7.7 Novartis
7.7.1 Company profile
7.7.2 Representative Immuno-Oncology Product
7.7.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Novartis
7.8 Gilead Sciences Inc.
7.8.1 Company profile
7.8.2 Representative Immuno-Oncology Product
7.8.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Gilead Sciences Inc.
7.9 Merck KGaA
7.9.1 Company profile
7.9.2 Representative Immuno-Oncology Product
7.9.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Merck KGaA
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMMUNO-ONCOLOGY
8.1 Industry Chain of Immuno-Oncology
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMMUNO-ONCOLOGY
9.1 Cost Structure Analysis of Immuno-Oncology
9.2 Raw Materials Cost Analysis of Immuno-Oncology
9.3 Labor Cost Analysis of Immuno-Oncology
9.4 Manufacturing Expenses Analysis of Immuno-Oncology
CHAPTER 10 MARKETING STATUS ANALYSIS OF IMMUNO-ONCOLOGY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
